Advanced HIV-1 infection is associated with gut dysbiosis, and it’s not known whether this is reversed with antiviral therapy. The ADVANZ-4 MISTRAL trial shows that dolutegravir restores gut microbiota in late-stage HIV1 patients better than darunavir, and that recovery is linked to improved immune reconstitution.
- Francesc Català-Moll
- Carlos Blázquez-Bondia
- Gloria Sempere
